Atossa Therapeutics (ATOS) EBITDA (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly EBITDA of -$9.9 million for Q1 2026, down 33.13% year-over-year from -$14.8 million in Q1 2025, and up 13.69% quarter-over-quarter from -$11.4 million in Q4 2025.
Atossa Therapeutics (ATOS) EBITDA (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported EBITDA for 16 consecutive years, with -$9.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 33.13% year-over-year to -$9.9 million; the TTM figure through Mar 2026 stood at -$39.6 million (down 41.14% YoY), while the FY2025 annual figure was -$37.1 million, down 34.47% from the prior year.
- EBITDA improved to -$9.9 million in Q1 2026 per ATOS's latest filing, from -$11.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$4.7 million in Q1 2022 and bottomed at -$11.4 million in Q4 2025.
- Historically, EBITDA has averaged -$7.9 million across 5 years, with a median of -$7.5 million in 2023.
- Annual changes were most pronounced in 2022 — EBITDA sank 68.56% — and 2024, when it climbed 20.71%.
- Atossa Therapeutics' EBITDA stood at -$8.1 million in 2022, then dropped by 10.83% to -$9.0 million in 2023, then increased by 20.71% to -$7.2 million in 2024, then tumbled by 59.92% to -$11.4 million in 2025, then advanced by 13.69% to -$9.9 million in 2026.
- Business Quant data shows ATOS's EBITDA at -$9.9 million in Q1 2026, -$11.4 million in Q4 2025, and -$9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 133.12 Mn |
| 10 | Atossa Therapeutics | 22.72 Mn | 22.72 Mn | - | -8.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.69 Mn |
| Mar 31, 2026 | -9.87 Mn |
| Dec 31, 2025 | -11.44 Mn |
| Sep 30, 2025 | -9.25 Mn |
| Jun 30, 2025 | -9.04 Mn |
| Mar 31, 2025 | -7.41 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Sep 30, 2024 | -6.39 Mn |
| Jun 30, 2024 | -7.11 Mn |
| Mar 31, 2024 | -6.98 Mn |
| Dec 31, 2023 | -9.02 Mn |
| Sep 30, 2023 | -7.47 Mn |
| Jun 30, 2023 | -7.79 Mn |
| Mar 31, 2023 | -7.10 Mn |
| Dec 31, 2022 | -8.14 Mn |
| Sep 30, 2022 | -8.21 Mn |
| Jun 30, 2022 | -6.60 Mn |
| Mar 31, 2022 | -4.75 Mn |
| Dec 31, 2021 | -4.83 Mn |
| Sep 30, 2021 | -5.16 Mn |